AI
PRME icon

Alphabet Inc’s Prime Medicine PRME Stock Holding History

Alphabet Inc’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$61.1M Hold
16,562,498
– – 0.06% 13
2026
Q1 		$57.6M Hold
16,562,498
– – 1.44% 11
2025
Q4 		$57.5M Hold
16,562,498
– – 2.23% 11
2025
Q3 		$91.8M Buy
16,562,498
+1,500,000
+10% +$6.09M 3.81% 10
2025
Q2 		$37.2M Hold
15,062,498
– – 1.74% 12
2025
Q1 		$30M Hold
15,062,498
– – 1.9% 12
2024
Q4 		$44M Hold
15,062,498
– – 2.56% 11
2024
Q3 		$58.3M Hold
15,062,498
– – 3.16% 11
2024
Q2 		$77.4M Hold
15,062,498
– – 3.92% 8
2024
Q1 		$105M Buy
15,062,498
+3,200,000
+27% +$24.3M 4.19% 9
2023
Q4 		$105M Hold
11,862,498
– – 4.87% 9
2023
Q3 		$113M Hold
11,862,498
– – 7.27% 5
2023
Q2 		$174M Sell
11,862,498
-1,422,190
-11% -$19.9M 9.34% 5
2023
Q1 		$163M Hold
13,284,688
– – 9.06% 2
2022
Q4 		$247M Buy
+13,284,688
New +$240M 14.34% 1

Other funds holding PRME

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Alphabet Inc's PRME Position: Q2 2026 in Review

Alphabet Inc held its Prime Medicine (PRME) position steady in Q2 2026 at 16,562,498 shares worth $61.1M. The position accounts for 0.06% of the portfolio, ranked #13.

Alphabet Inc first reported a position in PRME in Q4 2022 and has held it in 15 quarters since. The position peaked at $247M in Q4 2022. 187 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Alphabet Inc held 16,562,498 shares of Prime Medicine worth $61.1M as of Q2 2026.
  • Alphabet Inc left its Prime Medicine share count unchanged in Q2 2026.
  • Prime Medicine made up 0.06% of Alphabet Inc's portfolio in Q2 2026, its #13 holding.
  • Alphabet Inc first reported a position in Prime Medicine in Q4 2022 and has held it in 15 quarters since.
  • Alphabet Inc's Prime Medicine position peaked at $247M in Q4 2022.
  • 187 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Alphabet Inc's 13F filing for Q2 2026, filed 7 Aug 2026.